Roselie Achten
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Roselie Achten has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Marjolein de Bruin-Weller
Department of Dermatology and Allergology National Expertise Center for Atopic Dermatitis University Medical Center Utrecht Utrecht The Netherlands
9 shared publications - Daphne Suzanna Bakker
National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology University Medical Center Utrecht Utrecht The Netherlands
8 shared publications Femke van Wijk
Center for Translational Immunology University Medical Center Utrecht Utrecht University Utrecht the Netherlands
7 shared publicationsMarlies de Graaf
University Medical Center Utrecht
7 shared publicationsJoke de Boer
Department of Ophthalmology University Medical Center Utrecht Utrecht The Netherlands
5 shared publications- Marlies de Graaf
Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis University Medical Center Utrecht Utrecht The Netherlands
5 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Wiley in Clinical and Translational Allergy
- Vol. 16 (10) , e70208
Long‐Term Ocular Outcomes of Dupilumab in Atopic Dermatitis: Results From the BioDay Registry
Background: Dupilumab‐associated ocular surface disease (DAOSD) is the most reported side effect in dupilumab‐treated atopic dermatitis (AD) patients. We investigated the effect of long‐term dupilumab treatment on ocular surface disease (OSD), conjunctival goblet cells (GCs), and tear fluid dupilumab levels and proteins. Methods: This prospective study included moderate‐to‐severe AD patients at the University Medical Center Utrecht, the Netherlands. Patients initiating dupilumab between February 2020–October 2022 were eligible to participate in scheduled ophthalmological examinations alongside routine dermatological examinations at baseline, week 28, and last follow‐up (≥ 2 years). OSD severity was assessed using the Utrecht Ophthalmic Inflammatory and Allergic disease (UTOPIA) score, with DAOSD defined as a ≥ 3‐point increase from baseline. Conjunctival GC quantity and function were assessed with impression cytology. Dupilumab levels and proteins were measured in tear fluid. Results: Forty‐four patients were included. OSD was present in 90.9% ( n = 40/44) of patients at all visits. DAOSD occurred in 22.7% ( n = 10/44) of patients; 40.0% ( n = 4/10) persisted or newly developed at last follow‐up. Tear break‐up time decreased while tear production increased. Tear fluid dupilumab levels and AD‐related inflammatory proteins decreased over time. Conjunctival GCs decreased at last follow‐up compared to baseline. Mucin5AC (MUC5AC) production in CK19‐CD45‐MUC5AC + cells decreased at week 28 and remained stable at last follow‐up. Conclusion: OSD remained common during long‐term dupilumab treatment in AD patients. Some patients developed worsening of OSD compatible with DAOSD, including delayed onset, highlighting the need for continued awareness of ocular side effects among clinicians. Reduced MUC5AC production and declining AD‐related inflammatory proteins in tear fluid suggest changes in conjunctival homeostasis and ocular inflammation.
- 29 September 2026
- Published by Wiley in Clinical and Translational Allergy
- Vol. 16 (10) , e70208
Open AccessLong‐Term Ocular Outcomes of Dupilumab in Atopic Dermatitis: Results From the BioDay Registry
Background: Dupilumab‐associated ocular surface disease (DAOSD) is the most reported side effect in dupilumab‐treated atopic dermatitis (AD) patients. We investigated the effect of long‐term dupilumab treatment on ocular surface disease (OSD), conjunctival goblet cells (GCs), and tear fluid dupilumab levels and proteins. Methods: This prospective study included moderate‐to‐severe AD patients at the University Medical Center Utrecht, the Netherlands. Patients initiating dupilumab between February 2020–October 2022 were eligible to participate in scheduled ophthalmological examinations alongside routine dermatological examinations at baseline, week 28, and last follow‐up (≥ 2 years). OSD severity was assessed using the Utrecht Ophthalmic Inflammatory and Allergic disease (UTOPIA) score, with DAOSD defined as a ≥ 3‐point increase from baseline. Conjunctival GC quantity and function were assessed with impression cytology. Dupilumab levels and proteins were measured in tear fluid. Results: Forty‐four patients were included. OSD was present in 90.9% ( n = 40/44) of patients at all visits. DAOSD occurred in 22.7% ( n = 10/44) of patients; 40.0% ( n = 4/10) persisted or newly developed at last follow‐up. Tear break‐up time decreased while tear production increased. Tear fluid dupilumab levels and AD‐related inflammatory proteins decreased over time. Conjunctival GCs decreased at last follow‐up compared to baseline. Mucin5AC (MUC5AC) production in CK19‐CD45‐MUC5AC + cells decreased at week 28 and remained stable at last follow‐up. Conclusion: OSD remained common during long‐term dupilumab treatment in AD patients. Some patients developed worsening of OSD compatible with DAOSD, including delayed onset, highlighting the need for continued awareness of ocular side effects among clinicians. Reduced MUC5AC production and declining AD‐related inflammatory proteins in tear fluid suggest changes in conjunctival homeostasis and ocular inflammation.
- 2 November 2025
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 25 (11) , 1171-1192
Current treatment landscape of atopic dermatitis focusing on real-world evidence of dupilumab treatment
Atopic dermatitis (AD) is a prevalent chronic inflammatory skin disorder and has a considerable impact on patients' quality of life. Dupilumab, the first biologic approved for moderate-to-severe AD, is a human monoclonal antibody targeting the interleukin (IL)-4 receptor α, thereby blocking both IL-4 and IL-13 signaling, key drivers of type 2 inflammation in AD. Its introduction has marked a paradigm shift in the management of AD and paved the way for future therapies. As real-world evidence on biologics and Janus kinase (JAK) inhibitors is rapidly emerging, comprehensive and up-to-date reviews are important. This review primarily summarizes real-world data on dupilumab, with a focus on its effectiveness and safety in clinical practice, highlighting recent findings and their implications for optimizing patient management. Real-world evidence consistently confirms the high effectiveness, favorable safety profile, and long-term treatment durability of dupilumab across various patient subgroups, including children, elderly, and patients with different underlying immune and genetic profiles. Additionally, dupilumab has demonstrated beneficial effects in patients with comorbid asthma and food allergies. Emerging data further support its potential safety during pregnancy, breastfeeding, and (non-)live vaccinations. Dose tapering is often successful and lowers the socio-economic impact of dupilumab.
- 2 November 2025
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 25 (11) , 1171-1192
Current treatment landscape of atopic dermatitis focusing on real-world evidence of dupilumab treatment
Atopic dermatitis (AD) is a prevalent chronic inflammatory skin disorder and has a considerable impact on patients' quality of life. Dupilumab, the first biologic approved for moderate-to-severe AD, is a human monoclonal antibody targeting the interleukin (IL)-4 receptor α, thereby blocking both IL-4 and IL-13 signaling, key drivers of type 2 inflammation in AD. Its introduction has marked a paradigm shift in the management of AD and paved the way for future therapies. As real-world evidence on biologics and Janus kinase (JAK) inhibitors is rapidly emerging, comprehensive and up-to-date reviews are important. This review primarily summarizes real-world data on dupilumab, with a focus on its effectiveness and safety in clinical practice, highlighting recent findings and their implications for optimizing patient management. Real-world evidence consistently confirms the high effectiveness, favorable safety profile, and long-term treatment durability of dupilumab across various patient subgroups, including children, elderly, and patients with different underlying immune and genetic profiles. Additionally, dupilumab has demonstrated beneficial effects in patients with comorbid asthma and food allergies. Emerging data further support its potential safety during pregnancy, breastfeeding, and (non-)live vaccinations. Dose tapering is often successful and lowers the socio-economic impact of dupilumab.
- Top Cited PapersOpen Access
Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future Directions
Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases worldwide. The clinical presentation of AD is heterogeneous and is characterized by a relapsing and remitting course. Most patients suffer from mild AD while approximately 5% to 20% experience severe disease activity, which often requires systemic treatment. Before 2017, systemic treatment options were limited to broad immunosuppressants, which often had significant toxicity and limited effectiveness. Advances in understanding AD pathophysiology have led to the development of targeted biologic therapies, including dupilumab, tralokinumab, lebrikizumab, and nemolizumab. These monoclonal antibodies specifically block key pro‐inflammatory cytokines involved in AD, improving disease control and symptom relief. Dupilumab, the first approved biologic, inhibits IL‐4 and IL‐13 signaling, while tralokinumab and lebrikizumab selectively block IL‐13. Nemolizumab targets IL‐31, which plays a crucial role in pruritus. This review summarizes primarily real‐world data on the effectiveness and safety of these biologics, providing clinical guidance for their use and management of side effects. It also briefly discusses promising therapeutic targets currently in phase 3 trials.
Top Cited PapersOpen AccessBiologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future Directions
Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases worldwide. The clinical presentation of AD is heterogeneous and is characterized by a relapsing and remitting course. Most patients suffer from mild AD while approximately 5% to 20% experience severe disease activity, which often requires systemic treatment. Before 2017, systemic treatment options were limited to broad immunosuppressants, which often had significant toxicity and limited effectiveness. Advances in understanding AD pathophysiology have led to the development of targeted biologic therapies, including dupilumab, tralokinumab, lebrikizumab, and nemolizumab. These monoclonal antibodies specifically block key pro‐inflammatory cytokines involved in AD, improving disease control and symptom relief. Dupilumab, the first approved biologic, inhibits IL‐4 and IL‐13 signaling, while tralokinumab and lebrikizumab selectively block IL‐13. Nemolizumab targets IL‐31, which plays a crucial role in pruritus. This review summarizes primarily real‐world data on the effectiveness and safety of these biologics, providing clinical guidance for their use and management of side effects. It also briefly discusses promising therapeutic targets currently in phase 3 trials.
- Open Access
- 8 February 2024
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 54 (4) , 241-252
Ocular surface disease in moderate‐to‐severe atopic dermatitis patients and the effect of biological therapy
Atopic dermatitis (AD) is a chronic inflammatory skin disease for which new targeted therapies are currently available. Due to the increased rates of ocular surface disease (OSD) reported during treatment with these new targeted treatments, more insight into the occurrence and pathomechanism of OSD in moderate‐to‐severe AD patients is needed. Therefore, this review's first part highlights that most patients with moderate‐to‐severe AD already have characteristics of OSD before starting targeted treatment. Remarkably, not all AD patients with OSD report ocular symptoms. OSD in AD is associated with less conjunctival goblet cells (GC) compared to healthy controls. In addition, OSD severity in AD patients is associated with high AD activity, the presence of eyelid and/or facial eczema, and high levels of AD‐related severity biomarkers in tear fluid. The second part of this review highlights that pre‐existing ocular pathology (e.g. in combination with the use of ophthalmic medication or eyelid eczema) may be associated with the development of dupilumab‐associated ocular surface disease (DAOSD). During dupilumab treatment, DAOSD (which can be new‐onset OSD or worsening of pre‐existing OSD) is observed in approximately one‐third of the dupilumab‐treated AD patients. Anti‐inflammatory ophthalmic treatment improves DAOSD, and dose reduction of dupilumab may also be an effective treatment option. The pathomechanism of DAOSD is still not fully elucidated. In a prospective study low, but stable conjunctival GC numbers were observed in moderate‐to‐severe AD patients, before and during dupilumab treatment. However, the Mucin 5 AC (MUC5AC) expression of GCs decreased during dupilumab treatment, suggesting an impairment of the GC function by dupilumab treatment. In addition, higher dupilumab tear fluid levels were found in dupilumab‐treated AD patients with moderate‐to‐severe OSD compared to patients with no or mild OSD, whereas the dupilumab serum levels are similar. Clinicians should be aware of the frequent occurrence of OSD in moderate‐to‐severe AD patients, and a low‐threshold referral to an ophthalmologist is recommended.
- 8 February 2024
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 54 (4) , 241-252
Open AccessOcular surface disease in moderate‐to‐severe atopic dermatitis patients and the effect of biological therapy
Atopic dermatitis (AD) is a chronic inflammatory skin disease for which new targeted therapies are currently available. Due to the increased rates of ocular surface disease (OSD) reported during treatment with these new targeted treatments, more insight into the occurrence and pathomechanism of OSD in moderate‐to‐severe AD patients is needed. Therefore, this review's first part highlights that most patients with moderate‐to‐severe AD already have characteristics of OSD before starting targeted treatment. Remarkably, not all AD patients with OSD report ocular symptoms. OSD in AD is associated with less conjunctival goblet cells (GC) compared to healthy controls. In addition, OSD severity in AD patients is associated with high AD activity, the presence of eyelid and/or facial eczema, and high levels of AD‐related severity biomarkers in tear fluid. The second part of this review highlights that pre‐existing ocular pathology (e.g. in combination with the use of ophthalmic medication or eyelid eczema) may be associated with the development of dupilumab‐associated ocular surface disease (DAOSD). During dupilumab treatment, DAOSD (which can be new‐onset OSD or worsening of pre‐existing OSD) is observed in approximately one‐third of the dupilumab‐treated AD patients. Anti‐inflammatory ophthalmic treatment improves DAOSD, and dose reduction of dupilumab may also be an effective treatment option. The pathomechanism of DAOSD is still not fully elucidated. In a prospective study low, but stable conjunctival GC numbers were observed in moderate‐to‐severe AD patients, before and during dupilumab treatment. However, the Mucin 5 AC (MUC5AC) expression of GCs decreased during dupilumab treatment, suggesting an impairment of the GC function by dupilumab treatment. In addition, higher dupilumab tear fluid levels were found in dupilumab‐treated AD patients with moderate‐to‐severe OSD compared to patients with no or mild OSD, whereas the dupilumab serum levels are similar. Clinicians should be aware of the frequent occurrence of OSD in moderate‐to‐severe AD patients, and a low‐threshold referral to an ophthalmologist is recommended.
- Open Access
Dupilumab‐associated ocular surface disease in atopic dermatitis patients: Clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis
Background: Dupilumab‐associated ocular surface disease (DAOSD) is frequently reported as side effect in atopic dermatitis (AD) patients. Therefore, the aim of this study was to investigate the frequency and severity of DAOSD, ophthalmic treatment response and to learn more about the effect of dupilumab on conjunctival goblet cells (GC).Methods: This prospective study included dupilumab‐treated AD patients between February 2020 and June 2022 from the University Medical Centre Utrecht. Patients were examined by an ophthalmologist and a dermatologist before start (baseline), and after 4 and 28 weeks of dupilumab treatment. Ophthalmological examination was assessed by the Utrecht Ophthalmic Inflammatory and Allergic disease (UTOPIA) score. DAOSD was defined as an increase in UTOPIA score of ≥3 points from baseline. To quantify conjunctival GCs and to investigate the percentage of Cytokeratin 19 (CK19)‐CD45‐Mucin 5 AC (MUC5AC)+ cells, conjunctival impression cytology samples were analysed.Results: Ocular surface disease (OSD) was present in 91.3% (n = 63/69) patients at baseline. DAOSD was observed in 28.9% (n = 20/69) patients, in whom GC numbers remained stable and the percentage of CK19‐CD45‐MUC5AC+ cells decreased at onset of DAOSD compared with baseline. After 28 weeks of dupilumab treatment, DAOSD was seen in 14.5% (n = 10/69) patients. Of the 85.5% (n = 59/69) patients without DAOSD or with controlled DAOSD at Week 28, 40.7% (n = 24/59) patients received anti‐inflammatory ophthalmic drugs.Conclusions: Ocular surface disease is common in moderate‐to‐severe AD patients before starting dupilumab. During treatment with dupilumab DAOSD severity improves with early ophthalmic treatment. The decrease in percentage of CK19‐CD45‐MUC5AC+ cells during dupilumab treatment suggests an impairment of the GC function due to dupilumab treatment.
Open AccessDupilumab‐associated ocular surface disease in atopic dermatitis patients: Clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis
Background: Dupilumab‐associated ocular surface disease (DAOSD) is frequently reported as side effect in atopic dermatitis (AD) patients. Therefore, the aim of this study was to investigate the frequency and severity of DAOSD, ophthalmic treatment response and to learn more about the effect of dupilumab on conjunctival goblet cells (GC).Methods: This prospective study included dupilumab‐treated AD patients between February 2020 and June 2022 from the University Medical Centre Utrecht. Patients were examined by an ophthalmologist and a dermatologist before start (baseline), and after 4 and 28 weeks of dupilumab treatment. Ophthalmological examination was assessed by the Utrecht Ophthalmic Inflammatory and Allergic disease (UTOPIA) score. DAOSD was defined as an increase in UTOPIA score of ≥3 points from baseline. To quantify conjunctival GCs and to investigate the percentage of Cytokeratin 19 (CK19)‐CD45‐Mucin 5 AC (MUC5AC)+ cells, conjunctival impression cytology samples were analysed.Results: Ocular surface disease (OSD) was present in 91.3% (n = 63/69) patients at baseline. DAOSD was observed in 28.9% (n = 20/69) patients, in whom GC numbers remained stable and the percentage of CK19‐CD45‐MUC5AC+ cells decreased at onset of DAOSD compared with baseline. After 28 weeks of dupilumab treatment, DAOSD was seen in 14.5% (n = 10/69) patients. Of the 85.5% (n = 59/69) patients without DAOSD or with controlled DAOSD at Week 28, 40.7% (n = 24/59) patients received anti‐inflammatory ophthalmic drugs.Conclusions: Ocular surface disease is common in moderate‐to‐severe AD patients before starting dupilumab. During treatment with dupilumab DAOSD severity improves with early ophthalmic treatment. The decrease in percentage of CK19‐CD45‐MUC5AC+ cells during dupilumab treatment suggests an impairment of the GC function due to dupilumab treatment.
- Open Access
- 28 February 2023
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 32 (7) , 1150-1154
Non-Infectious Uveitis Secondary to Dupilumab Treatment in Atopic Dermatitis Patients Shows a Pro-Inflammatory Molecular Profile
Severe uveitis is a rare complication of interleukin-4 receptor alpha blocking by dupilumab in topic dermatitis (AD) patients. The aim of this study was to describe five moderate-to-severe AD patients who developed uveitis during dupilumab treatment and to compare the proteomic profile of aqueous humor (AqH) of dupilumab-associated uveitis (n=3/5 available samples) with non-infectious uveitis (n=27) and cataract controls (n=11). Included patients were treated at the University Medical Center Utrecht (the Netherlands). Active dupilumab-associated uveitis complicated by serous detachment, cystoid macular edema, or secondary glaucoma developed within a median of 6.0 months (interquartile range 2.3–16.5 months) after starting dupilumab. Uveitis resolved after discontinuation of dupilumab and/or treatment with local or systemic corticosteroids. Proteomic profiling of AqH revealed that the molecular profile of dupilumab-associated uveitis resembled that of non-infectious uveitis. In conclusion, dupilumab-associated uveitis is a severe adverse event of dupilumab therapy, requiring urgent referral to an ophthalmologist.
- 28 February 2023
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 32 (7) , 1150-1154
Open AccessNon-Infectious Uveitis Secondary to Dupilumab Treatment in Atopic Dermatitis Patients Shows a Pro-Inflammatory Molecular Profile
Severe uveitis is a rare complication of interleukin-4 receptor alpha blocking by dupilumab in topic dermatitis (AD) patients. The aim of this study was to describe five moderate-to-severe AD patients who developed uveitis during dupilumab treatment and to compare the proteomic profile of aqueous humor (AqH) of dupilumab-associated uveitis (n=3/5 available samples) with non-infectious uveitis (n=27) and cataract controls (n=11). Included patients were treated at the University Medical Center Utrecht (the Netherlands). Active dupilumab-associated uveitis complicated by serous detachment, cystoid macular edema, or secondary glaucoma developed within a median of 6.0 months (interquartile range 2.3–16.5 months) after starting dupilumab. Uveitis resolved after discontinuation of dupilumab and/or treatment with local or systemic corticosteroids. Proteomic profiling of AqH revealed that the molecular profile of dupilumab-associated uveitis resembled that of non-infectious uveitis. In conclusion, dupilumab-associated uveitis is a severe adverse event of dupilumab therapy, requiring urgent referral to an ophthalmologist.
- Open Access
- 16 January 2023
- Published by Wiley in Clinical and Translational Allergy
- Vol. 13 (1) , e12221
High dupilumab levels in tear fluid of atopic dermatitis patients with moderate‐to‐severe ocular surface disease
Background: The patho‐mechanism of ocular surface disease (OSD) in dupilumab‐treated atopic dermatitis (AD) patients remains unclear. The aim of this study is to measure dupilumab levels in tear fluid and serum, and relate these findings to the severity of OSD during dupilumab treatment in AD patients.Methods: This prospective study included dupilumab‐treated moderate‐to‐severe AD patients who were seen by a dermatologist and an ophthalmologist before the start of dupilumab (baseline), and after 4 and 28 weeks of dupilumab treatment. Dupilumab levels in tear fluid and serum were measured by liquid chromatography coupled with tandem mass spectrometry (LC‐MS/MS). Additionally, a pilot study was conducted to measure dupilumab on conjunctival epithelial cells using flow cytometry and LC‐MS/MS.Results: At baseline, 89.6% (n = 43/48) of the patients had OSD, with 50.0% having moderate‐to‐severe OSD. After 28 weeks of dupilumab treatment, the median dupilumab tear fluid levels were 0.55 mg/L (IQR 0.35–1.31) and 0.29 mg/L (IQR 0.16–0.60) in patients with moderate‐to‐severe OSD and patients with no or mild OSD, respectively (p = 0.02). Dupilumab levels could be detected on conjunctival epithelial cells of 5 AD patients treated with dupilumab for 4 weeks.Conclusion: Patients with moderate‐to‐severe OSD had higher dupilumab tear fluid levels compared to patients with no or mild OSD, indicating that dupilumab reaches the ocular surface. Dupilumab was also detected in conjunctival cell suspensions and was found to directly bind CD45‐conjunctival epithelial cells. This suggests that AD‐induced changes of the conjunctival epithelium may play a role in the development of OSD as well as increased local drug availability.
- 16 January 2023
- Published by Wiley in Clinical and Translational Allergy
- Vol. 13 (1) , e12221
Open AccessHigh dupilumab levels in tear fluid of atopic dermatitis patients with moderate‐to‐severe ocular surface disease
Background: The patho‐mechanism of ocular surface disease (OSD) in dupilumab‐treated atopic dermatitis (AD) patients remains unclear. The aim of this study is to measure dupilumab levels in tear fluid and serum, and relate these findings to the severity of OSD during dupilumab treatment in AD patients.Methods: This prospective study included dupilumab‐treated moderate‐to‐severe AD patients who were seen by a dermatologist and an ophthalmologist before the start of dupilumab (baseline), and after 4 and 28 weeks of dupilumab treatment. Dupilumab levels in tear fluid and serum were measured by liquid chromatography coupled with tandem mass spectrometry (LC‐MS/MS). Additionally, a pilot study was conducted to measure dupilumab on conjunctival epithelial cells using flow cytometry and LC‐MS/MS.Results: At baseline, 89.6% (n = 43/48) of the patients had OSD, with 50.0% having moderate‐to‐severe OSD. After 28 weeks of dupilumab treatment, the median dupilumab tear fluid levels were 0.55 mg/L (IQR 0.35–1.31) and 0.29 mg/L (IQR 0.16–0.60) in patients with moderate‐to‐severe OSD and patients with no or mild OSD, respectively (p = 0.02). Dupilumab levels could be detected on conjunctival epithelial cells of 5 AD patients treated with dupilumab for 4 weeks.Conclusion: Patients with moderate‐to‐severe OSD had higher dupilumab tear fluid levels compared to patients with no or mild OSD, indicating that dupilumab reaches the ocular surface. Dupilumab was also detected in conjunctival cell suspensions and was found to directly bind CD45‐conjunctival epithelial cells. This suggests that AD‐induced changes of the conjunctival epithelium may play a role in the development of OSD as well as increased local drug availability.
- Open Access
- 22 December 2022
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 53 (2) , 239-243
Biomarkers in tear fluid of dupilumab‐treated moderate‐to‐severe atopic dermatitis patients
- 22 December 2022
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 53 (2) , 239-243
Open AccessBiomarkers in tear fluid of dupilumab‐treated moderate‐to‐severe atopic dermatitis patients
- 26 August 2022
- Published by Morressier GmbH
ESDR093 - Tear fluid dupilumab levels of patients with moderate-to-severe atopic dermatitis and ocular surface disease
Ocular surface disease (OSD) is a common adverse event in dupilumab-treated patients with atopic dermatitis (AD). The pathomechanism remains uncl | POSTER
- 26 August 2022
- Published by Morressier GmbH
ESDR093 - Tear fluid dupilumab levels of patients with moderate-to-severe atopic dermatitis and ocular surface disease
Ocular surface disease (OSD) is a common adverse event in dupilumab-treated patients with atopic dermatitis (AD). The pathomechanism remains uncl | POSTER
- 26 August 2022
- Published by Morressier GmbH
ESDR126 - Serum dupilumab levels after 16 weeks of treatment are not associated with treatment response or side effects in atopic dermatitis patients
The registered dose of dupilumab for adult atopic dermatitis (AD) patients is 300mg every other week (Q2W). However, it is unknown whether serum | POSTER
- 26 August 2022
- Published by Morressier GmbH
ESDR126 - Serum dupilumab levels after 16 weeks of treatment are not associated with treatment response or side effects in atopic dermatitis patients
The registered dose of dupilumab for adult atopic dermatitis (AD) patients is 300mg every other week (Q2W). However, it is unknown whether serum | POSTER